Skip to content
ESPT
MARKETS / NASDAQ / Health care / Pharmaceuticals / UPC
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Universe Pharmaceuticals Inc. UPC

7 fiscal years on record · USD · FY2025 reported · SEC filings only
$17.9B
▼ 22.4% YoY
$-3.7B
$-5.3B

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Universe Pharmaceuticals Inc., through its PRC operating entities, manufactures, markets, sells and distributes TCMD products targeting the elderly. It currently produces 13 varieties of TCMD products, which are sold in approximately 261 cities across 30 provinces in China. Through its subsidiary Universe Trade, it also sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces and dietary supplements manufactured by third-party pharmaceutical companies. The PRC operating entities' major customers are pharmaceutical distributors, hospitals, clinics and drugstore chains, primarily located in Jiangxi Province, Jiangsu Province, Guangdong Province, Hubei Province, Fujian Province, Guangxi Province and Shandong Province, and 23 other provinces in China. As of September 30, 2025, it had a total of 216 employees, all of whom are located in China.

Written from the business description in Universe Pharmaceuticals INC's annual report to the U.S. Securities and Exchange Commission, filed 29 January 2026. Every sentence was checked against that document before publication.

Growth

USD 17.9B
Revenue, FY2025 · full 7-year series below
Revenue $B Net income $B
FY2025 · Revenue 17.9 · Net income -3.7
15B30B-4B-8B
201920222025
Compound annual growth
+663.4%
+257.2%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +257.2% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−21 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -16.3% · Net -20.6%
10%20%30%-10%-20%-30%
201920222025
ROE
FY2025 · ROE -7.2%
20%40%60%-10%-20%
201920222025
Three returns, three denominators.
Gross margin35.3%
Operating margin-16.3%
Net margin-20.6%
EBITDAUSD -2.4B

Each USD of equity lost 7 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $B
FY2025 · FCF -5.3
-4B-8B
201920222025
Net buybacks $M Dividends $M
FY2019 · Dividends 16.0 · Net buybacks ·
10M20M
2019
Dividends paid·
Net buybacks·
Share of profit·
Consecutive raises·

Total assetsUSD 69.3B
EquityUSD 56.1B
CashUSD 33.6B
Gross debtUSD 2.1B
Net debtUSD -31.5B
Current ratio4.07×

The company holds more cash than debt.

The 7-year record

7 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
UPC, 7-year financial record
Metric 2025202420232022202120202019
Revenue $B17.923.032.30.00.00.00.0
Operating income $B−2.9−8.0−4.0−0.00.00.00.0
EBITDA $B−2.4−7.5−3.5−0.00.00.00.0
Income tax $B◌0.62.30.00.00.00.0
Net income $B−3.7−8.7−6.6−0.00.00.00.0
Free cash flow $B−5.3−9.71.1−0.0−0.00.00.0
EPS, diluted $−8.06−626.96−1089.21−1309.113.580.470.47
Dividend / sh $◌◌◌◌◌◌◌
Payout %——————212
ROE %−7.2−23.8−20.8−0.033.445.561.0
Shares out B0.000.000.020.020.020.02◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

MCK · COR · CAH · JNJ · HCA · LLY
Provenance

Company facts, as filed

How we verify · 0 failures in 33 reconciliationsAUDITED

Reconciled in 7 of the 7 fiscal years we could check. 26 checks were skipped: the balance sheet is not tagged before 2020. 12 checks were skipped: EPS is not tagged before 2019. 12 checks were skipped: revenue is not tagged before 2019.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code F4
Fiscal year endsSeptember 30
SEC categoryemerging growth company
Data on record since2019

Share this section

Download image